BioCryst Pharmaceuticals. has filed a patent for methods of making the active forms of galidesivir and azasugar nucleoside analogues, which are potent anti-viral compounds used for the treatment, suppression, and prevention of viral infections. The patent claims a method of preparing compound 2b1 or its salt by combining compound 2b or its salt with a phosphorylation reagent. The compounds have various substituents and can be used for broad spectrum antiviral treatment. GlobalData’s report on BioCryst Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on BioCryst Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. BioCryst Pharmaceuticals's grant share as of September 2023 was 37%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230303611A1) describes a method for preparing a compound called 2b1 or a salt thereof. The method involves combining compound 2b or a salt thereof with a phosphorylation reagent, resulting in the production of compound 2b1 or a salt thereof. Compound 2b is represented by a specific structure, with various substituents and functional groups. The method allows for the preparation of compound 2b1 or its salt without the need for isolation.
In addition to the above method, the patent also describes subsequent steps in the synthesis process. Compound 2b1 or its salt can be further combined with a pyrophosphate reagent to produce compound 2c or a salt thereof. The pyrophosphate reagent can be pyrophosphoric acid or a pyrophosphate salt, such as bis(tributylammonium)pyrophosphate. Furthermore, compound 2c or its salt can be combined with a deprotection reagent, such as aqueous ammonia or an amine, to produce compound 2 or a salt thereof.
The patent also includes a step involving the combination of compound 2a or its salt with an acylating reagent, resulting in the production of compound 2b or a salt thereof. The acylating reagent has a specific structure, with X representing a leaving group, which can be O-alkyl. Ethyl trifluoroacetate is given as an example of an acylating reagent. The combination of compound 2a or its salt with the acylating reagent may involve the use of a base, such as triethylamine.
The synthesis process described in the patent also includes purification steps. Compound 2 or its salt can be purified using chromatography, specifically column chromatography. This chromatography process may involve anion-exchange chromatography and reverse-phase chromatography, potentially in a specific sequence. Aqueous triethylammonium bicarbonate can be used as a mobile phase in the chromatography process.
The patent also provides the structures of various compounds, including compound 2b1, compound 2c, compound 2, and compound 2a. These compounds have specific structures with various substituents and functional groups.
Overall, the patent describes a method for preparing compound 2b1 or its salt, along with subsequent steps and purification processes. The method involves the combination of specific compounds and reagents, allowing for the efficient synthesis of these compounds.
To know more about GlobalData’s detailed insights on BioCryst Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
